Atorvastatin reduced soluble receptors of TNF-alpha in systemic lupus erythematosus
Carregando...
Data
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Federal de Minas Gerais
Descrição
Tipo
Artigo de periódico
Título alternativo
Primeiro orientador
Membros da banca
Resumo
The aim of this study was to evaluate the efficacy of atorvastatin to reduce the plasma levels of TNF system molecules(TNF-α, sTNFR1 and sTNFR2) and to assess their association with risk factors for accelerate atherosclerosis and clinical disease activity scores in SLE patients.In a previous study, 64 female SLE patients received 20 mg/day of atorvastatin and 24 SLE patients (non-treated group)were followed for 8 weeks. Plasma levels of TNF-α, sTNFR 1 and sTNFR 2 were measured by ELISA, at baseline and atthe end of the
study.The plasma levels of sTNFR1 and sTNFR 2 showed a positive correlation with SLEDAI score. We also found a positivecorrelation between TNF-α and sTNFR 1 levels and SLICC score. Patients with current nephritis and patients with anti-dsDNA antibodies presented higher sTNFR1 and sTNFR2 levels. Patients with abdominal obesity and arterial hypertension also had higher plasma levels of soluble receptors. At the end of 8 weeks, we observed a significant decrease in sTNFR1 plasma levels in patients receiving atorvastatin [median (percentile), 876.5 (717–1284 pg/ml) vs. 748 (629.6–917.3 pg/ml),p=0.03], without difference regarding TNF-α and sTNFR2 plasma levels. The SLEDAI and SLICC scores were independent determinants of the plasma levels of sRTNF1.Atorvastatin reduced soluble receptors of TNF-α. The plasma levels of TNF-α, sTNFR1 and sTNFR2 may play a role in
SLE activity and atherosclerosis, and might be evaluated as targets for new therapies.
Abstract
Assunto
Lúpus Eritematoso Sistêmico, Aterosclerose, Atorvastatina
Palavras-chave
aterosclerose, atorvastatin, systemic lupus erythematosus
Citação
Curso
Endereço externo
https://www.clinexprheumatol.org/abstract.asp?a=9060